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This study was undertaken to examine the interaction between the combination of angiogenesis and blood vessel invasion (BVI) and
haematogenous metastasis, and to determine the prognostic significance of that combination in predicting 20-year relapse-free
survival (RFS) and overall survival (OS) rates in primary breast cancer. Five hundred and nine patients were studied. We investigated
11 factors, including average microvessel count (AMC)/BVI, lymph-node status (n), clinical tumour size (T), histological grade (HG),
lymphatic vessel invasion (LVI), p53, proliferating cell nuclear antigen (PCNA), c-erbB-2, mitotic index (MI), apoptotic index, and
tumour necrosis (TN). Blood vessel invasion was detected by both factor VIII-related antigen and elastica van Gieson staining. To
evaluate the best objective method to quantify microvessel density in angiogenesis, AMC was employed. The rate of AMC-high and
BVI-positive tumours was 32.6 and 29.3%, respectively. That of both AMC-high and BVI-positive tumours was 10.1%. Univariate
analysis showed that AMC/BVI, n, T, HG, LVI, p53, PCNA, MI, and TN were significantly predictive of RFS and OS. By multivariate
analysis, AMC/BVI was the strongest independent prognostic factor for 20-year RFS (relative risk (RR)¼5.5; Po0.0001) and for
20-year OS (RR¼4.3; Po0.0001). Lymph-node status was still considered a powerful prognostic indicator; however, the
combination of AMC and BVI provided more reliable prognostic information than lymph-node status for haematogenous dissemination.
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There have been many reports about the prognostic factors in
breast cancer of which lymph-node status remains a major
conventional prognostic factor and has been clinically used as a
measure for disseminating the disease, while some investigators
have reported that lymph-node metastases have not necessarily
been associated with haematogenous dissemination (Fisher et al,
1981; Menard et al, 1994; Braun et al, 2000). Moreover, several
additional biologic markers, such as angiogenesis, p53, proliferat-
ing cell nuclear antigen (PCNA), c-erbB-2, apoptosis, mitosis, and
necrosis have been related to tumour proliferation and develop-
ment, but their effects on tumour haematogenous metastasis are
by no means clear, and there are still controversies regarding the
best possible prognostic index for breast cancer patients (Thor
et al, 1992; Gilchrist et al, 1993; Zhang et al, 1998; Kato et al, 1999;
Beenken et al, 2001; Sirvent et al, 2001).
Some studies have suggested that microvessel density indicated
representative angiogenesis of the tumour and was an independent
and highly significant prognostic factor for both node-negative
and node-positive patients (Weidner et al, 1991; Gasparini et al,
1994; Simpson et al, 1996; Heimann et al, 1996; Kato et al, 2001).
However, other authors reported that angiogenesis did not predict
recurrence in patients with primary breast cancer (Van Hoef et al,
1993; Goulding et al, 1995). The significance of angiogenesis
remains controversial because of studies that varied in patient
selection, length of time of patient follow-up, antibody used to
detect endothelial cells, sample size, method of counting micro-
vessels, and the patients’ race.
Recent reports have suggested that peritumour lymphatic and
blood vessel invasion (BVI) (vascular invasion) (Lee et al, 1990;
Mansi et al, 1991; Fox et al, 1997) or peritumour lymphatic vessel
invasion (LVI) (Clemente et al, 1992; Gasparini et al, 1994; Lauria
et al, 1996) are significant prognostic factors. However, there are a
few recent studies of the prognostic significance of peritumour BVI
(Gasparini et al, 1994; Lauria et al, 1996; Kato et al, 2000, 2002). It
has been more difficult to identify invasion of small vessels and
capillaries and in the larger vessels surrounded by elastic tissue in
breast cancer in routine haematoxylin and eosin (H&E)-stained
tissue sections than in gastric or colorectal cancer. A wide range of
frequencies has been reported for BVI among patients with breast
cancer and the prognostic significance of BVI has not yet been
made clear (Weigand et al, 1982; van de Velde et al, 1986;
Gasparini et al, 1994; Lauria et al, 1996; Kato et al, 2000, 2002).
Tumours that have acquired the ability of high neovascularisa-
tion are likely to involve blood vessels. However, all tumours with
high neovascularisation do not have the ability to invade vessels.
Gould et al (1983) reported that bronchial carcinoid tumours are
highly vascular, but they do not spread beyond the lung.
Angiogenesis is necessary for a tumour to grow but not sufficient
for it to metastasise. Thus, there are definitely biological
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ydifferences between the ability of tumours to form high
neovascularisation and their ability to invade blood vessels. And
both the growth of tumours dependent on angiogenesis and the
tumours spreading beyond the primary site are dependent on
access to the vasculature and are important for haematogenous
metastasis.
This study was undertaken to examine the interaction between
the combination of angiogenesis and BVI and haematogenous
dissemination, and to determine the absolute and relative values of
that combination using both Factor VIII-related antigen and
elastica van Gieson staining, as we detected by our method
published previously (Kato et al, 2001, 2002). Moreover, the
clinicopathological significance of p53, PCNA, c-erbB-2, and
apoptosis, relatively new prognostic factors, and conventional
prognostic factors, especially lymph-node status was evaluated in
predicting relapse-free survival (RFS) and overall survival (OS)
rates with a long-term follow-up in Japanese patients with breast
cancer.
PATIENTS AND METHODS
Patients
Data for this study were collected from 509 breast cancer patients
selected from those operated on between 1971 and 1990 at Tokyo
Women’s Medical University Hospital for whom we had sufficient
clinical and pathologic material to determine all the biological
markers. The distribution of the main clinicopathologic data for
the entire 509-patient population is given in Table 1. Two hundred
and sixty-four of these patients (51.9%) were treated with radical
mastectomy, 153 patients (30.0%) with modified radical mastect-
omy, and 92 patients (18.1%) with extended radical mastectomy.
Although we had no formal protocol for adjuvant therapy,
adjuvant chemotherapy was administered to patients with T2, T3
or lymph-node positive tumours. Two hundred and ninety-two of
those patients (57.3%) received adjuvant chemotherapy including
mitomycin C (given intravenously after mastectomy; total doses
ranged from 20 to 40mg for 4–6 weeks) and/or 5-fluorouracil (or
its derivatives) were taken orally for 5 years. Postmenopausal
patients with positive oestrogen receptors were treated with
adjuvant hormone therapy from 1983. Ninety-eight patients
(19.3%) received adjuvant chemotherapy and hormone therapy,
and 25 patients (4.9%) received adjuvant hormone therapy. No
adjuvant treatment was given to 94 patients (18.5%). The median
follow-up duration of the patients was 9 years (range, 1–20).
Pathological studies
The original histologic sections of biopsy and mastectomy
specimens were reviewed. Paraffin-embedded tissue samples of
4.5mm thick sections stained with H&E were histopathologically
assessed. The pathologic specimens were reviewed without any
knowledge of the eventual clinical outcome. Conventional
clinicopathologic features were observed and recorded, including
the clinical tumour size, histological grade, LVI, and tumour
necrosis (TN). The clinical tumour size was determined based on
the TNM classification, the histological grade was decided based
on the Bloom–Richardson grade (Bloom and Richardson, 1957),
and LVI was determined based on H&E staining. Sections of the
breast tumour that were stained with H&E were used to select the
maximal area of all the cut surfaces of the tumour that included the
invasive component.
Apoptotic cells were assessed in (H&E) stained sections. The
apoptotic cells were defined as cells showing marked condensation
of chromatin and cytoplasm, cytoplasmic fragments containing
condensed chromatin, and intra- and extracellular chromatin
fragments with a diameter of approximately 2mm (Wyllie et al,
1981). Apoptotic cells were counted using a standard light
microscope at a 400 magnification ( 40 objective, 0.152mm
2
per field) in 10 randomised fields. Apoptotic index (AI) was scored
as negative (o10 apoptotic cells per 10 fields) and positive (X10
apoptotic cells per 10 fields). The mitotic index (MI) was
determined by a method described in a previous report (Baak
Table 1 Clinicopathologic characteristics of 509 patients
Characteristics No. of patients (%)
Patients enrolled 509
Age (years)
Median 49
Range 15–84
Survival follow-up (years)
Median 9
Range 1–20
Recurrence 103 (20.2)
Deaths 83 (16.3)
Menopausal status
Pre 256 (50.3)
Post 228 (44.8)
Unknown 25 (4.9)
Clinical tumour size (T)
T1 194 (38.1)
T2 251 (49.3)
T3 64 (12.6)
Lymph-node status
Negative 307 (60.3)
Positive 202 (39.7)
Average microvessel count
Low 327 (67.4)
High 158 (32.6)
Blood vessel invasion
Negative 357 (70.7)
Positive 148 (29.3)
AMC/BVI
Low/negative 235 (48.7)
High/negative 105 (21.7)
Low/positive 94 (19.5)
High /positive 49 (10.1)
Lymphatic vessel invasion
Negative 387 (76.8)
Positive 117 (23.2)
Histological grade
HG I (Well) 219 (43.5)
HG II (Moderate) 141 (28.0)
HG III (Poor) 144 (28.5)
p53
Negative 334 (69.7)
Positive 145 (30.3)
c-erbB-2
Negative 305 (65.3)
Positive 162 (34.7)
PCNA
Negative 258 (53.3)
Positive 226 (46.7)
MI
Negative 327 (65.1)
Positive 175 (34.9)
AI
Negative 397 (79.1)
Positive 105 (20.9)
Tumor necrosis
None 309 (61.6)
Central 76 (15.1)
Comedo 117 (23.3)
Histological classification
Infiltrating ductal carcinoma 466 (92.4)
Infiltrating lobular carcinoma 20 (4.0)
Others 18 (3.6)
PCNA¼proliferating cell nuclear antigen; MI¼mitotic index; AI¼apoptotic index.
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yet al, 1985). The nuclear membrane and the clear zone in the centre
had to be absent, and clear, hairy extensions of nuclear material
had to be present for them to be counted. Two parallels, and each
of the two clearly separate chromosome clumps, were both
counted as two mitotic figures. The number of mitotic figures
was identified in 10 high-power microscopic fields (objective
magnification  40). The MI were scored as negative (o10 mitotic
figures per 10 fields) and positive (X10 mitotic figures per 10
fields). The necrosis was divided into two categories. Coagulation
necrosis in the centre area of cancer nests was defined as central
necrosis, and necrosis in the intraductal component was defined as
comedo necrosis (Kato et al, 1997).
Immunohistochemical determinations
Immunostains for PCNA, p53, c-erbB-2, and factor VIII-related
antigen were performed on the paraffin sections using the
streptavidin–biotin–immunoperoxidase method as previously
described (Kato et al, 1999). Briefly, the primary antibodies
employed were an affinity-purified monoclonal anti-human-PCNA
antibody (PC10, Novocastra Laboratories, Newcastle, UK) at a
1:100 dilution, polyclonal anti-p53 antibody (CM1, Novocastra
Laboratories, UK) diluted at a 1:100, polyclonal anti-human c-
erbB-2 protein antibody (Dako, Copenhagen, Denmark) at a 1:100
dilution, and monoclonal antibody (von Willebrand factor F8/86,
Dako, Copenhagen, Denmark) applied at 1:200. After immunos-
taining, the sections were counterstained with haematoxylin. The
growth fraction by PCNA staining was evaluated by counting 500
consecutive cells on one slide for each tumour with a  400
magnification and an index of positive cells to the total number of
cells (labeling index (LI)) was made. Labelling index was evaluated
and scored as negative (omean of LI) and positive (Xmean of LI).
As above, the growth fraction by p53-protein staining was
evaluated by counting 500 consecutive cells and LI was made.
Labelling index was evaluated and scored as negative (omean of
LI) and positive (Xmean of LI). For c-erbB-2 protein expression,
membrane staining in at least 50% of the tumour cells was
considered positive according to the criteria of Wright et al (1989).
Blood vessel invasion was determined using factor VIII-related
antigen staining and elastica van Gieson staining as previously
described (Kato et al, 2001, 2002). We morphologically classified
the BVI into four types according to the patterns of these blood
vessels invaded by cancer cells (Figure 1). Type I was a blood
vessel directly infiltrated by tumour cells (Figure 1A), type II was a
blood vessel filled with tumour cell emboli (Figure 1B–D), type III
was a blood vessel with growth of cancer cells between the
endothelium and the lamina elastica interna (Figure 1E–G), and
type IV was a blood vessel with floating tumour cells (Figure 1H).
The distinction between lymphatic vessels and blood vessels is
difficult and is sometimes arbitrarily determined. While endothe-
lial cells in the lymphatic vessels were occasionally stained by
factor VIII-related antigen staining, the pattern of staining in the
lymphatic vessels was very faint, discontinuous, and inconsistent
in contrast to the intense and continuous staining observed in the
vascular endothelium (Figure 1I). On this basis, blood vessels
could be differentiated from lymphatic vessels in our study. All
doubtful cases were considered to be negative. Blood vessel
invasion detected by elastica van Gieson staining was defined by
criteria similar to those of Weigand et al (1982). Blood vessels were
identified by the following characteristics. Erythrocytes in the
lumen, an endothelial cell lining, and the presence of elastic tissue
around large vessels and ducts were identified by a zone of
acidophilic nonelastic tissue inside the elastic ring surrounding the
ducts (Figure 1J). When it was difficult to distinguish BVI from
ductal carcinoma in situ (DCIS), the case was considered to be
negative. All blood microvessels (capillaries and small venulae)
were highlighted by staining endothelial cells with factor VIII-
related antigen staining. Single brown-stained endothelial cells or
clusters of endothelial cells, with or without a lumen, were counted
as individual microvessels. To evaluate the best objective method
to quantify microvessel density in angiogenesis, the average
microvessel count (AMC) per square millimeter was employed
(Kato et al, 1999, 2001). One maximal area in one slide of all the
cut surfaces exhibiting invasive components in each tumour was
scanned at high power ( 200), and the number of microvessels in
the areas along the border between cancer nests and the stroma
was recorded. The average number of microvessels in all the fields
scanned at high power was calculated giving the mean AMC. The
segregation point of the parameter at 54.0 for AMC was deter-
mined by the Cox proportional hazards regression model (Cox, 1972).
Statistical analysis
Statistical analysis of the data was performed with the Survival
Tools for Statview-J 4.5 package (Abacus Concepts, Berkeley, CA,
USA) on an Apple Power Macintosh 8100/100AV. The association
between each parameter was assessed by Pearson’s correlation
coefficient. We examined the univariate relation between prog-
nostic indicators and 20-year RFS and OS by fitting Kaplan–Meier
survival curves (Kaplan and Meier, 1958) to various levels of the
prognostic indicators. We then looked for differences among the
curves using the log-rank test (Mantel, 1966). The Cox propor-
tional hazards regression model was also used for the multivariate
analysis (Cox, 1972).
RESULTS
Clinical outcome
Among the 509 patients, there were 103 tumour-related recur-
rences and 83 tumour-related deaths (Table 1). In addition, there
were 23 patients who were lost in the follow-up, 389 patients who
are alive, and 14 patients who died of unrelated causes without
recurrent tumours, with follow-up examinations of up to 20 years
(median, 9 years).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– "
Figure 1 Representative examples of BVI and LVI. (1) Blood vessels directly infiltrated by cancer cells (Type I, A: factor VIII-related antigen staining,
haematoxylin counter stain, original magnification:  100). (2) Blood vessels filled with tumour cell emboli and lymphatic vessel invasion (Type II, B: H&E
staining, C: elastica van Gieson staining, D: factor VIII-related antigen staining, haematoxylin counter stain, original magnification: B–D  50). The arrowhead
indicates a BVI and arrows indicate LVI with floating tumour cells. The endothelium of lymphatic vessels by factor VIII-related antigen staining was not stained.
(3) Blood vessels with growth of cancer cells between endothelium and lamina elastica interna (Type III, E: H&E staining, F: elastica van Gieson staining, G:
factor VIII-related antigen staining, haematoxylin counter stain, original magnification: E–G  50). (4) Blood vessels with floating tumour cells (Type IV, H:
factor VIII-related antigen staining, haematoxylin counter stain, original magnification:  200). (5) The arrowhead indicates a lymphatic vessel with floating
tumour cells and arrows indicate blood vessels. The pattern of staining in the lymphatic vessel by factor VIII-related antigen staining was very faint,
discontinuous, and inconsistent in contrast to the intense and continuous staining observed in the vascular endothelium (I: factor VIII-related antigen staining,
haematoxylin counter stain, original magnification:  100). (6) Dilated normal ducts were identified by a zone of acidophilic non-elastic tissue inside the
elastic ring surrounding the ducts. The arrowhead indicates the elastic ring and the arrow indicates acidophilic nonelastic tissue. (J: elastica van Gieson
staining, original magnification:  50). (7) In non-BVI, the pattern is similar to type III. There is no growth of cancer cells between the endothelium and the
lamina elastica interna, while some cancer cells invaded the lamina elastica externa. The arrow indicates cancer cells invading the lamina elastica externa (K:
HE staining, L: elastica van Gieson staining, M: factor VIII-related antigen staining, haematoxylin counter stain, original magnification: K–M  50).
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The rate of AMC-high and BVI-positive tumours was 158 of
485 (32.6%), 148 of 505 (29.3%), respectively. That of both
AMC-high and BVI-positive tumours was 49 of 483 (10.1%)
(Table 1). Table 2 shows the association between each para-
meter. When comparing BVI and clinical tumour size, lymph-
node status, histological grade, LVI, p53, PCNA, and MI,
there were significant correlations among them. On the other
hand, AMC weakly correlated with PCNA and c-erbB-2, but
AMC/BVI correlated with lymph-node status, LVI, and PCNA
(Table 2).
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The prognostic factors found to be significantly associated with
20-year RFS were AMC/BVI (Po0.0001, Figure 2A), clinical
tumour size, lymph-node status, histological grade, LVI, p53,
PCNA, MI, and TN (Table 3). Moreover, AMC/BVI (Po0.0001,
Figure 2B), clinical tumour size, lymph-node status, histological
grade, LVI, p53, PCNA, c-erbB-2, MI, and TN were associated with
20-year OS. However, AI was not associated with either 20-year
RFS or OS (Table 3).
Multivariate analysis
Table 4 shows that AMC/BVI was the strongest independent
prognostic factor for 20-year RFS (relative risk (RR)¼5.5;
Po0.0001) and for 20-year OS (RR¼4.3; Po0.0001) by multi-
variate analysis.
Stratification by lymph-node status
When stratified by lymph-node status, a significant impact of
AMC/BVI on 20-year RFS or OS was seen in patients with node-
negative and -positive carcinomas by univariate analysis
(Po0.0001 or Po0.0001, and Po0.0001 or Po0.0001, respec-
tively). We fitted a model with four factors: AMC/BVI, clinical
tumour size, histological grade, and p53, in patients with node-
negative carcinoma, and compared them by multivariate analysis.
AMC/BVI was a significant independent factor for 20-year RFS or
OS (RR¼19.1; 95% confident interval (95% CI) ¼4.6–79.5;
Po0.0001, or RR¼20.3; 95% CI¼3.3–127.1; P¼0.0013, respec-
tively). Moreover, AMC/BVI was a significant independent factor
for 20-year RFS or OS in patients with node-positive carcinoma on
multivariate analysis (RR¼3.4; 95% CI¼1.7–6.7; P¼0.0005, or
RR¼2.9; 95% CI¼1.4–6.2; P¼0.0049, respectively). Patients with
node-positive carcinoma who had AMC-high and BVI-positive
tumours had a higher risk of cancer-related death than the patients
with node-negative carcinoma who had AMC-low and BVI-
Table 2 Pearson’s correlation between each parameter
Parameter BVI AMC AMC/BVI Tn HG LVI p53 PCNA c-erbB-2 MI AI Necrosis
BVI 1
AMC 0.032 1
(0.5054)
AMC/BVI 0.459 0.897 1
(o0.001) (o0.001)
T 0.245  0.069 0.045 1
(o0.001) (0.1497) (0.3463)
n 0.283 0.026 0.132 0.349 1
(o0.001) (0.5877) (0.0060) (o0.001)
HG 0.153  0.148  0.065 0.319 0.164 1
(0.0014) (0.0019) (0.1776) (o0.001) (0.0006)
LVI 0.261 0.083 0.183 0.208 0.422 0.048 1
(o0.001) (0.0828) (0.0001) (o0.001) (o0.001) (0.3182)
p53 0.145  0.032 0.031 0.107 0.180 0.229 0.035 1
(o0.001) (0.5073) (0.5191) (0.0257) (0.0002) (o0.001) (0.4703)
PCNA 0.231 0.099 0.181 0.312 0.447 0.179 0.219 0.179 1
(o0.001) (0.0386) (0.0001) (o0.001) (o0.001) (0.0002) (o0.001) (0.0002)
c-erbB-2 0.014 0.112 0.092 0.140 0.210 0.123 0.071 0.132 0.186 1
(0.7725) (0.0191) (0.0561) (0.0036) (0.0252) (0.0100) (0.1384) (0.0060) (o0.001)
MI 0.184  0.060 0.032 0.250 0.107 0.594 0.080 0.107 0.171 0.053 1
(0.0001) (0.2085) (0.5002) (o0.001) (0.0252) (o0.001) (0.0964) (0.0257) (0.0003) (0.2697)
AI 0.060  0.014 0.019 0.090  0.022 0.383  0.029 0.105 0.089 0.076 0.528 1
(0.2138) (0.7719) (0.6989) (0.0604) (0.6464) (o0.001) (0.5492) (0.0281) (0.0625) (0.1157) (o0.001)
Necrosis 0.038  0.131  0.096 0.140  0.049 0.370  0.023 0.167 0.042 0.026 0.478 0.365 1
(0.4256) (0.0063) (0.0445) (0.0035) (0.3083) (o0.001) (0.6324) (0.0005) (0.3833) (0.5892) (o0.001) (o0.001)
BVI¼blood vessel invasion; AMC¼average microvessel count; T¼clinical tumour size; n¼lymph-node status; HG¼histological grade; LVI¼lymphatic vessel invasion; PCNA
proliferating cell nuclear antigen; MI¼mitotic index; AI¼apoptotic index; P-values are given in parentheses.
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Figure 2 Kaplan–Meier survival curves for all patients. (A) RFS stratified
by AMC and BVI. (B) OS related to AMC and BVI.
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Po0.0001, RR¼61.0; 95% CI¼14.0–266.6; Po0.0001, respec-
tively, Figures 2A and B). There was no significant difference in 20-
year RFS or OS between patients with node-negative carcinoma
who had AMC-high and BVI-positive tumours, and patients with
node-positive carcinoma who had AMC-low and BVI-negative
tumours (P¼0.9522 and P¼0.6867, respectively, Figures 3A
and B).
Characteristics of the treatment
We examined the effect of treatment in all patients for RFS and OS.
The modality of operation was not associated with RFS or OS.
However, adjuvant chemotherapy was significantly associated with
OS but not with RFS (RR¼1.6; 95% CI¼1.0–2.5; P¼0.0428, or
RR¼1.2; 95% CI¼0.8–1.8; P¼0.4927, respectively). Using
interaction terms in the Cox proportional hazards model, we
examined variations in the importance of AMC/BVI across
treatment subgroups. In the subgroup of 94 patients without
adjuvant therapy, the relative risk of both RFS and OS also
associated with AMC/BVI was significant (RR¼4.7; 95% CI¼1.5–
14.9; P¼0.0085, and RR¼4.3; 95% CI¼1.4–13.8; P¼0.0126,
respectively). On the other hand, in the subgroup of 283 patients
with chemotherapy, the relative risk of both RFS and OS associated
with AMC/BVI remained significantly elevated (RR¼6.8; 95%
CI¼3.0–15.4; Po0.0001, and RR¼6.7; 95% CI¼2.6–16.8;
Po0.0001, respectively).
DISCUSSION
Results of the present study confirm AMC/BVI as the strongest
independent prognostic factor for 20-year RFS and OS in Japanese
patients with breast cancer. AMC/BVI was also a significant
independent factor for 20-year RFS or OS in patients with both
node-negative and positive carcinomas; especially, the effect of the
presence of AMC/BVI was clearer in patients with node-negative
carcinomas than in those with node-positive carcinomas.
Some clinical studies suggested that to use an antibody to CD31
may be superior to using factor VIII-related antigen (Horak et al,
1992; Fox et al, 1994), however, the other study reported that this
greater sensitivity of anti-CD31 of vascular endothelium did not
yield more discriminating results for predicting survival outcome
than results produced with factor VIII-related antigen (Gasparini
et al, 1994). At that point, it may lack some acuracy; however,
many stromal vessels can be stained very well and be taken in to
account by factor VIII-related antigen staining as we published
previously (Kato et al, 1999). When the authors compared AMC
with the highest microvessel density in one or three fields (the hot
spots) in the previous study, AMC was a more reliable factor than
that of the hot spots (Kato et al, 1999). Therefore, we used AMC in
this study. The results show that AMC was an independent
prognostic factor, but its prognostic impact was not as strong as
lymph-node status and clinical tumour size.
The rate of BVI fell within the range of 4.2–52.0% as observed in
other studies (Teel and Sommers, 1964; Friedell et al, 1965; Sampat
Table 3 Univariate analysis of the value of prognostic factors for RFS and OS
RFS OS
Variable RR 95% CI P-value RR 95% CI P-value
AMC
Low vs high 1.7 1.1–2.5 0.0149 1.4 0.9–2.2 0.1613
BVI
Negative vs positive 4.1 2.8–6.1 o0.0001 4.5 2.9–7.1 o0.0001
AMC/BVI
Low/negative vs high/negative 1.7 0.9–3.1 0.1234 1.3 0.6–2.8 0.5025
Low/negative vs low/positive 4.0 2.3–6.8 o0.0001 4.3 2.4–7.9 o0.0001
Low/negative vs high/positive 7.0 4.0–12.3 o0.0001 6.3 3.3–11.9 o0.0001
Clinical tumour size (T)
T1 vs T2 2.1 1.2–3.6 0.0062 2.1 1.1–3.9 0.0182
T1 vs T3 8.4 4.8–14.7 o0.0001 10.2 5.5–19.2 o0.0001
Lymph-node status
Negative vs positive 5.1 3.3–7.8 o0.0001 5.8 3.5–9.7 o0.0001
Histological grade
HG I vs HG II 1.9 1.1–3.2 0.0217 2.6 1.3–4.9 0.0048
HG I vs HG III 3.7 2.3–6.0 o0.0001 5.6 3.1–10.1 o0.0001
Lymphatic vessel invasion
Negative vs positive 3.3 2.2–4.8 o0.0001 3.8 2.4–5.8 o0.0001
p53
Negative vs positive 2.6 1.7–3.8 o0.0001 2.4 1.6–3.8 o0.0001
PCNA
Negative vs positive 3.2 2.0–4.9 o0.0001 3.6 2.2–6.0 o0.0001
c-erbB-2
Negative vs positive 1.4 0.9–2.2 0.0971 1.8 1.1–2.9 0.0131
MI
Negative vs positive 2.4 1.6–3.5 o0.0001 2.9 1.9–4.5 o0.0001
AI
Negative vs positive 1.5 0.9–2.3 0.0711 1.4 0.9–2.3 0.1491
Tumour necrosis
None vs comedo 1.4 0.8–2.2 0.2050 1.5 0.9–2.6 0.1048
None vs central 2.2 1.3–3.5 0.0019 2.5 1.5–4.3 0.0006
RFS¼relapse-free survival; OS¼overall survival; RR¼relative risk; AMC¼average microvessel count; BVI¼blood vessel invasion; PCNA¼proliferating cell nuclear antigen;
MI¼mitotic index; AI¼apoptotic index; Hazards ratio from Cox regression analysis.
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yet al, 1977; Cooperative Breast Cancer Group, 1978; Martin et al,
1987; Fisher et al, 1993; Kister et al, 1996; Lauria et al, 1996; Kato
et al, 2002). In this study, BVI in the breast cancer patients we
observed was seen in 148 cases (29.3%). On the other hand, the
rate of BVI examined by Lauria et al (1996) was 4.2%. They
detected BVI using H&E staining alone, and the prevalence of BVI
was particularly low in their study. In the previous study, when we
evaluated BVI by H&E staining alone, the rate of BVI presented in
6.5%, which was similar to the study by Lauria et al (Lauria et al,
1996; Kato et al, 2002). By H&E staining alone, it was difficult to
detect blood vessels filled with tumour cell emboli, to distinguish
BVI from pseudoemboli resulting from shrinkage where cancer
cells peeled off from the ducts because of poor fixing, to
distinguish between small blood vessel invasion and LVI, to find
the blood vessels with cancer cells growing between the
endothelium and the lamina elastica interna, and to distinguish
BVI from DCIS covered with elastic fibre (Figure 1, Kato et al,
2002). Therefore, there was a possibility of overlooking some kinds
of blood vessel invasion using H&E staining alone. When Weigand
et al (1982) and others (Sampat et al, 1977) examined the
prognostic value of BVI, BVI correlated significantly with a high
rate of recurrence. The results of our study suggest that BVI is an
adverse prognostic factor among patients with breast cancer as
well as lymph-node status. However, when Lauria et al (1996)
examined the prognostic value of BVI, it was associated with
shorter survival by univariate analysis but not significantly an
independent factor by multivariate analysis. These discrepancies
may be because of some technical reasons, especially the staining
methods of BVI, number of cases studied, the different follow-up
period and different races.
Average microvessel count and BVI retained an independent
significance in association with RFS or OS by multivariate analysis
(Table 4). Independent of lymph-node status, if there were AMC-
low and BVI-negative tumours, we observed similar, excellent,
long-term survival. Moreover, we used both factors to define a
high-risk subset of all the tumours in cases that experienced a
48.1% recurrence or a 57.4% survival probability within 17 years
(Figure 1A and B). There are likely to be worse prognoses when
carcinomas acquire the ability to form AMC-high and BVI-positive
tumours, which then become more important indications of
outcome than lymph-node status and clinical tumour size. Our
study suggests that even when tumours acquire a high degree of
neovascularisation, it is impossible to form distant metastases
without BVI and that AMC/BVI might be the most important and
strongest predictive factor for tumour haemtogenous metastasis.
In recent studies, it has been suggested that examination for
bone marrow micrometastasis using immunocytochemical meth-
ods in breast cancer patients would be useful as a prognostic
marker (Braun et al, 2000). Moreover, other investigators reported
that an assessment of tumour angiogenesis and vascular invasion
give a reliable indication of the likelihood of the presence of bone
marrow micrometastasis in patients with breast cancer and both
processes contribute to metastases (Mansi et al, 1991; Fox et al,
1997). However, as they did not distinguish BVI from LVI, the
meaning of the pathway of haematogenous metastastasis remains
unclear. Although some investigators have indicated it impractical
to distinguish between the blood and lymphatic vessel systems as
independent routes of tumour dissemination because they are so
interrelated (Fisher and Fisher, 1966), the present authors
examined the difference between BVI and LVI in order to
distinguish the different pathways to distant metastases. As
vascular invasion includes the routes of both lymphatic and
haematogenous dissemination, BVI alone may show haematogen-
ous dissemination more accurately than vascular invasion.
Haematogenous metastasis can be considered a complex process
of cascading interregulated sequential steps. Average microvessel
count and BVI include many steps that are necessary for
haematogenous dissemination, that is, they are the results of
tumour invasion to extracelluar matrices and basement mem-
branes, entering the circulatory system, and activating angiogen-
esis at both the primary and distant sites. Our results suggest that
tumours can spread directly via the blood-vascular system from
their initial growth sites, and that biologically the significance of
the combination of AMC and BVI is clearly more important than
that of either BVI or AMC alone.
There are some reports that indicate adequate locoregional
treatment for early breast cancer may prevent secondary
dissemination (Hellman and Harris, 1987; Arriagada et al, 1995).
However, Fisher et al (1981) maintained that breast cancer is a
systemic disease and positive lymph nodes are not impor-
tant instigators of distant disease. Several investigators have found
no correlation between nodal metastases and bone-marrow
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Figure 3 Kaplan–Meier survival curves for AMC-low and BVI-negative
and AMC-high and BVI-positive patients. (A) RFS stratified by node, AMC,
and BVI. (B) OS related to by node, AMC, and BVI.
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ymetastases (Harbeck et al, 1994; Menard et al, 1994). Moreover,
Menard et al (1994) reported that pathological nodal status was not
a more reliable prognostic factor than the primary tumour score,
including tumour size, grading, laminin receptor, and c-erbB-2.
Our results suggest that tumours can spread directly through the
blood-vascular system from their initial growth sites, and that
lymph-node status was still considered a powerful prognostic
indicator; however, biologically the combination of AMC and BVI
is more significant than lymph-node status for tumour haemato-
genous dissemination.
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